Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B.
- Citation:
- J Clin Oncol vol 26 (14) 2364-72
- Year:
- 2008
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Secondary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- Parents:
- None
- Children:
- None
- Program:
- TRP
- Primary Committee:
- Correl Sci NOS
- Sec. Committees:
- Pharmas:
- Grants:
- CA33601, P30 CA016672, CA77406, UO1CA64507, CA77651, CA60138, CA35279, UO1CA64061, CA47559, CA31946, R01CA45708
- Corr. Author:
- Authors:
- Michael P DiGiovanna David F Stern Susan Edgerton Gloria Broadwater Lynn G Dressler Daniel R Budman I Craig Henderson Larry Norton Edison T Liu Hyman B Muss Donald A Berry Daniel F Hayes Ann D Thor
- Networks:
- Study
- Alliance-8541
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- Keywords:
- Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Chemotherapy, Adjuvant, Cyclophosphamide, Disease-Free Survival, Dose-Response Relationship, Drug, Doxorubicin, Enzyme Activation, Female, Fluorouracil, Gene Dosage, Humans, Immunohistochemistry, In Situ Hybridization, Fluorescence, Lymphatic Metastasis, Neoplasm Staging, Phosphorylation, Receptor, ErbB-2